Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead Vt Regulatory News (BVT)

Share Price Information for Baronsmead Vt (BVT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.00
Bid: 51.50
Ask: 54.50
Change: 0.00 (0.00%)
Spread: 3.00 (5.825%)
Open: 53.00
High: 53.00
Low: 53.00
Prev. Close: 53.00
BVT Live PriceLast checked at -
Baronsmead Venture Trust is an Investment Trust

To achieve long-term investment returns for private investors by investing primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on AIM.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allotment of Shares and Total Voting Rights

26 Jan 2024 14:30

RNS Number : 1047B
Baronsmead Venture Trust PLC
26 January 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY MEMBER STATE OF THE EEA (OTHER THAN ANY MEMBER STATE OF THE EEA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETED), OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY INVESTMENTS IN ANY JURISDICTION.

Baronsmead Venture Trust plc

LEI: 213800VQ1PQHOJXDDQ88

26 January 2024

Allotment of Shares and Total Voting Rights

The Board of Baronsmead Venture Trust plc (the "Company") announced on 24 November 2023 that the Company, together with Baronsmead Second Venture Trust plc, had published a prospectus (the "Prospectus") in relation to offers for subscription to raise up to £30 million in aggregate with the discretion to utilise over-allotment facilities to raise up to a further £20 million in aggregate (the "Offers" and each an "Offer").

On 26 January 2024 and in accordance with the Allotment Formula set out in the Prospectus, the Company allotted 16,089,415 Ordinary Shares of 10 pence each (the "New Ordinary Shares") in the capital of the Company pursuant to the first allotment under the Offer conditional only on Admission (the timetable for which is set out in more detail below). The New Ordinary Shares were issued at prices of between 57.95 pence per New Ordinary Share and 61.23 pence per New Ordinary Share, depending on the amount of Offer Costs, any Initial Commission waived, any Initial Adviser Charges, any Early Bird Discount associated with an Application and based on the net asset value per Ordinary Share as at 18 January 2024 (as announced on 24 January 2024, being the last published net asset value per Ordinary Share).

Application will shortly be made for the New Ordinary Shares to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the premium segment of London Stock Exchange plc's main market for listed securities ("Admission"). It is expected that Admission will occur and dealing will commence in the New Ordinary Shares on or around 2 February 2024. When issued, the New Ordinary Shares will rank pari passu with the existing Ordinary Shares.

As a result of the issue, the total number of Ordinary Shares in issue will be 365,814,589 (excluding the 31,896,083 Ordinary Shares currently held in Treasury) with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company will be 365,814,589. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

The New Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 10 business days of allotment. The New Ordinary Shares will be eligible for settlement through CREST with effect from Admission.

Unless the context requires otherwise, terms defined in the Prospectus have the same meaning where used in this announcement.

For further information please contact:

Baronsmead VCT Investor Relations

020 7382 0999

baronsmeadvcts@greshamhouse.com

Important Information

This Announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This Announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in Baronsmead Venture Trust plc or Baronsmead Second Venture Trust plc (together the "Companies") in any jurisdiction, including in or into Australia, Canada, Japan, the Republic of South Africa, the United States or any member state of the EEA (other than any member state of the EEA where the Companies' securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this Announcement except on the basis of information in the prospectus (the "Prospectus") in its final form, published on 24 November 2023 by Baronsmead Venture Trust plc and Baronsmead Second Venture Trust plc, together with the supplementary prospectus published on 19 January 2024 (the "Supplementary Prospectus"), in connection with the Offer. A copy of the Prospectus and Supplementary Prospectus is available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website (http://www.baronsmeadvcts.co.uk). Approval of the Prospectus and Supplementary Prospectus by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus and Supplementary Prospectus. Potential investors are recommended to read the Prospectus and Supplementary Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Companies' securities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVRUNRSRSVUAUAR
Date   Source Headline
10th Jun 20217:00 amRNSTransaction in Own Shares
4th Jun 20216:00 pmRNSNet Asset Value(s)
28th May 202110:45 amRNSCorrection: Half-year Report
27th May 20213:37 pmRNSHalf-year Report
7th May 20214:15 pmRNSNet Asset Value(s)
15th Apr 20215:00 pmRNSNet Asset Value(s)
1st Apr 20219:57 amRNSTotal Voting Rights
30th Mar 20216:04 pmRNSTransaction in Own Shares
18th Mar 202112:56 pmRNSDirector/PDMR Shareholding
18th Mar 202112:46 pmRNSIssue of New Shares
9th Mar 202111:56 amRNSSale of shares from Treasury
3rd Mar 20215:15 pmRNSNet Asset Value(s)
1st Mar 202112:09 pmRNSTotal Voting Rights
26th Feb 20213:24 pmRNSIssue of New Shares
22nd Feb 20212:32 pmRNSOffer for Subscription - Update
16th Feb 20214:19 pmRNSResult of AGM
15th Feb 20219:25 amRNSUpdate on Fundraising
5th Feb 202110:00 amRNSNet Asset Value(s)
1st Feb 202112:18 pmRNSTotal Voting Rights
29th Jan 20212:56 pmRNSDirector/PDMR Shareholding
29th Jan 20211:44 pmRNSDirector/PDMR Shareholding
29th Jan 202112:36 pmRNSIssue of New Shares
27th Jan 20215:22 pmRNSTransaction in Own Shares
27th Jan 202111:25 amRNSPublication of Supplementary Prospectus
21st Jan 20215:45 pmRNSNet Asset Value(s)
6th Jan 202110:35 amRNSUpdate on Fundraising
4th Jan 202112:05 pmRNSTotal Voting Rights
22nd Dec 20202:38 pmRNSDirector Declaration
18th Dec 20207:00 amRNSIssue of Equity
17th Dec 20205:46 pmRNSTransaction in Own Shares
4th Dec 20204:15 pmRNSNet Asset Value(s)
3rd Dec 20205:56 pmRNSAnnual Financial Report for the y/e 30/09/2020
1st Dec 202010:36 amRNSTotal Voting Rights
10th Nov 20203:52 pmRNSDirector/PDMR Shareholding
10th Nov 20203:24 pmRNSDirector/PDMR Shareholding
10th Nov 20203:23 pmRNSDirector/PDMR Shareholding
10th Nov 20202:41 pmRNSDirector/PDMR Shareholding
10th Nov 20201:43 pmRNSIssue of New Shares
5th Nov 20201:00 pmRNSNet Asset Value(s)
3rd Nov 20205:08 pmRNSCorrection: Transaction in Own Shares
3rd Nov 20205:00 pmRNSCorrection: Transaction in Own Shares
2nd Nov 202011:15 amRNSTotal Voting Rights
27th Oct 20203:48 pmRNSTransaction in Own Shares
20th Oct 20207:00 amRNSNet Asset Value(s)
7th Oct 20205:11 pmRNSOffer update – Extension of Earlybird Rebate
1st Oct 202011:00 amRNSTotal Voting Rights
29th Sep 202010:53 amRNSTransaction in Own Shares
17th Sep 20209:00 amRNSPublication of a Prospectus
16th Sep 20203:35 pmRNSDirector/PDMR Shareholding
11th Sep 20204:45 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.